10x Genomics reports Q1 2026 results today carrying a notable short position that has been quietly unwinding — and analysts who have spent the past month lifting their targets ahead of the print.
Short interest at 14.6% of the free float is meaningful, but the direction of travel matters more than the level. Shorts pulled back roughly 5.6% over the past week after touching a recent high on April 27, and borrow conditions offer little encouragement to new bears: cost to borrow has drifted down about 10% over the week to a modest 0.44%, and availability in the lending market remains loose, with only around 14% of the lending pool currently in use — well below the 52-week high of 28.6%. Days to cover runs at 7.1, which leaves the short base exposed to any positive surprise but not in a structurally squeezed position. Options traders are leaning bullish rather than defensive: the put/call ratio of 0.20 is below its 20-day average of 0.21, sitting near the lower end of its past-year range and nowhere close to the 0.63 annual high. The stock has rallied 12.6% over the week to $22.74, gaining 3.3% on Wednesday alone.
Analysts have been remarkably consistent in one direction. Targets moved higher across the board in April: Canaccord raised to $32 from $22 while maintaining Buy, and Bank of America lifted to $30 from $21 on a Neutral rating — a meaningful upgrade in conviction even without a ratings change. Barclays moved to $30 from $22, and Citigroup nudged its Neutral target to $24 from $18. William Blair upgraded to Outperform in late March. The consensus mean target of $24.00 sits roughly in line with the current price, but individual bull-side targets now cluster in the high $20s to low $30s, implying the Street broadly sees more room from here than the headline average suggests. The bull case centres on consumables growth dramatically outpacing instrument revenue, with Chromium reaction volumes on an upward trajectory. Bears point to the damage already done: revenues were squeezed by double-digit pricing pressure in 2024, the stock has lost more than 90% from its 2021 peak, and meaningful improvement is not widely expected until 2027.
The institutional picture adds one noteworthy detail: FMR (Fidelity) added over 6.6 million shares in its most recent filing, lifting its stake to 15.1% — the largest single institutional position on record. ARK Investment Management added nearly 780,000 shares to reach 9.8% of shares outstanding. Those are active, conviction-weighted buyers accumulating into the same price range where the CEO, Serge Saxonov, has been selling modestly through a scheduled programme — small transactions totalling roughly $735,000 since late February, all at low significance scores and consistent with a pre-arranged plan.
Today's print is less about whether 10x Genomics can stabilise volumes and more about whether management can show that the consumables growth narrative is translating into numbers — and whether the pricing headwinds that defined 2024 are finally starting to ease.
See the live data behind this article on ORTEX.
Open TXG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
